Marco Pérez

2.7k total citations · 1 hit paper
39 papers, 2.2k citations indexed

About

Marco Pérez is a scholar working on Oncology, Materials Chemistry and Molecular Biology. According to data from OpenAlex, Marco Pérez has authored 39 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 14 papers in Materials Chemistry and 12 papers in Molecular Biology. Recurrent topics in Marco Pérez's work include Catalytic Processes in Materials Science (12 papers), Gas Sensing Nanomaterials and Sensors (7 papers) and Cancer Cells and Metastasis (6 papers). Marco Pérez is often cited by papers focused on Catalytic Processes in Materials Science (12 papers), Gas Sensing Nanomaterials and Sensors (7 papers) and Cancer Cells and Metastasis (6 papers). Marco Pérez collaborates with scholars based in Spain, United States and Venezuela. Marco Pérez's co-authors include José A. Rodríguez, Jonathan P. Evans, Jan Hrbek, P. Liu, Suli Ma, Amancio Carnero, Jonathan C. Hanson, Lucı́a González, Tomàš Jirsàk and Sandra Muñoz-Galván and has published in prestigious journals such as Science, Journal of the American Chemical Society and The Journal of Chemical Physics.

In The Last Decade

Marco Pérez

38 papers receiving 2.2k citations

Hit Papers

Activity of CeO x and TiO x Nanoparticles Grown on Au... 2007 2026 2013 2019 2007 250 500 750

Peers

Marco Pérez
Prasanta Dutta United States
Christopher M. Brown United States
Jing Yan China
Yuehui Li China
Youjin Lee South Korea
Prasanta Dutta United States
Marco Pérez
Citations per year, relative to Marco Pérez Marco Pérez (= 1×) peers Prasanta Dutta

Countries citing papers authored by Marco Pérez

Since Specialization
Citations

This map shows the geographic impact of Marco Pérez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Pérez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Pérez more than expected).

Fields of papers citing papers by Marco Pérez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Pérez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Pérez. The network helps show where Marco Pérez may publish in the future.

Co-authorship network of co-authors of Marco Pérez

This figure shows the co-authorship network connecting the top 25 collaborators of Marco Pérez. A scholar is included among the top collaborators of Marco Pérez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco Pérez. Marco Pérez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Martín‐Broto, Javier, Jerónimo Martínez-García, David S. Moura, et al.. (2023). Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A. Signal Transduction and Targeted Therapy. 8(1). 405–405. 15 indexed citations
2.
Martín‐Broto, Javier, David S. Moura, Andrés Redondo, et al.. (2022). Phase II trial of palbociclib in advanced sarcoma overexpressing CDK4 gene excluding dedifferentiated liposarcoma (DD LPS): A study from the Spanish Group for Research on Sarcoma (GEIS).. Journal of Clinical Oncology. 40(16_suppl). 11511–11511. 3 indexed citations
3.
Pérez, Marco, José Manuel García-Heredia, Blanca Felipe‐Abrio, et al.. (2020). Sarcoma stratification by combined pH2AX and MAP17 (PDZK1IP1) levels for a better outcome on doxorubicin plus olaparib treatment. Signal Transduction and Targeted Therapy. 5(1). 195–195. 13 indexed citations
5.
Muñoz-Galván, Sandra, Blanca Felipe‐Abrio, Eva M. Verdugo‐Sivianes, et al.. (2020). Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness. Molecular Cancer. 19(1). 7–7. 92 indexed citations
6.
Bui, Tung, Jonathan Rennhack, Ling Chen, et al.. (2019). Functional Redundancy between β1 and β3 Integrin in Activating the IR/Akt/mTORC1 Signaling Axis to Promote ErbB2-Driven Breast Cancer. Cell Reports. 29(3). 589–602.e6. 34 indexed citations
8.
Ferrer, Irene, Àlvaro Quintanal-Villalonga, Sonia Molina‐Pinelo, et al.. (2018). MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma. Journal of Experimental & Clinical Cancer Research. 37(1). 195–195. 25 indexed citations
9.
Muñoz-Galván, Sandra, Antonio Lucena-Cacace, Marco Pérez, et al.. (2018). Tumor cell-secreted PLD increases tumor stemness by senescence-mediated communication with microenvironment. Oncogene. 38(8). 1309–1323. 40 indexed citations
10.
Verdugo‐Sivianes, Eva M., Mónica Pereira Garcia, Lola E. Navas, et al.. (2018). PO-433 Prognostic relevance of PP1 in breast cancer. ESMO Open. 3. A401–A401.
11.
García-Heredia, José Manuel, Antonio Lucena-Cacace, Eva M. Verdugo‐Sivianes, Marco Pérez, & Amancio Carnero. (2017). The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB. Clinical Cancer Research. 23(14). 3871–3883. 53 indexed citations
12.
Pérez, Marco, Antonio Lucena-Cacace, Luis Miguel Marín Gómez, et al.. (2016). Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src. Oncotarget. 7(22). 33111–33124. 30 indexed citations
13.
Muñoz-Galván, Sandra, Gabriel Gutiérrez, Marco Pérez, & Amancio Carnero. (2015). MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFκB Activation in Breast Cancer. Molecular Cancer Therapeutics. 14(6). 1454–1465. 23 indexed citations
14.
Ferrer, Irene, Eva M. Verdugo‐Sivianes, María Ángeles Castilla, et al.. (2015). Loss of the tumor suppressor spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors. Oncogene. 35(21). 2777–2788. 29 indexed citations
15.
Blanco‐Aparicio, Carmen, et al.. (2013). Conditional Transgenic Expression of PIM1 Kinase in Prostate Induces Inflammation-Dependent Neoplasia. PLoS ONE. 8(4). e60277–e60277. 26 indexed citations
16.
Pérez, Marco, Juan Manuel Praena‐Fernández, Blanca Felipe‐Abrio, et al.. (2013). MAP17 and SGLT1 Protein Expression Levels as Prognostic Markers for Cervical Tumor Patient Survival. PLoS ONE. 8(2). e56169–e56169. 45 indexed citations
17.
Rodriguez, JoséA., X. Wang, W. Wen, et al.. (2008). Water-gas shift activity of Cu surfaces and Cu nanoparticles supported on metal oxides. Catalysis Today. 143(1-2). 45–50. 115 indexed citations
18.
Zhao, Xueying, Jan Hrbek, José A. Rodríguez, & Marco Pérez. (2005). Reaction of SO2 with Cu/TiO2(110): Effects of size and metal-oxide interactions in the chemical activation of Cu nanoparticles. Surface Science. 600(1). 229–239. 13 indexed citations
19.
Rodríguez, José A., et al.. (2005). Reaction of SO2 with Au∕CeO2(111): Importance of O vacancies in the activation of gold. The Journal of Chemical Physics. 122(24). 241101–241101. 48 indexed citations
20.
Rodríguez, José A., Tomàš Jirsàk, Marco Pérez, et al.. (2000). Studies on the Behavior of Mixed-Metal Oxides and Desulfurization:  Reaction of H2S and SO2with Cr2O3(0001), MgO(100), and CrxMg1-xO(100). Journal of the American Chemical Society. 122(49). 12362–12370. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026